The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

Gout was associated with a 30% higher risk for chronic opioid exposure based on US Veteran's Health Administration data. Patients with gout in the United States are at greater risk for chronic opioid ...

HealthDay News — The US Food and Drug Administration (FDA) has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).

In a prospective cohort study, researchers examined how early life medical risk factors for individuals born preterm compare with those born full-term in adulthood.

Researchers assessed whether a childhood asthma subgroup at high-risk for ARI could be identified using natural language processing algorithms as a “digital biomarker.” ...

About 80% of parents currently choose to follow CDC guidelines to vaccinate their babies for hepatitis B at birth.

Private equity hospitals reduced ED and ICU salary expenditures after acquisition relative to control hospitals .

Researchers examined the association between levels of vitamin D and risk for MS among White and Black military personnel in the US.

HealthDay News — People living with type 2 diabetes experience double the risk for incident sepsis versus matched individuals without diabetes, according to a study presented at the annual meeting of ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

North Carolina and Idaho are cutting their Medicaid programs to bridge budget gaps, raising fears that providers will stop ...

Women with acute stroke are less likely than men to be accurately identified as having a stroke in the prehospital setting, ...